<DOC>
	<DOCNO>NCT03004508</DOCNO>
	<brief_summary>Primary objective : The primary objective study assess effect Ginkgo biloba L. leaf extract ( IDN 5933 ) comparison placebo human subject treat therapeutic dos 6 month level DNA damage genomic instability , measure Comet Assay Micronucleus assay , respectively . Secondary objective : The secondary objective study provide preliminary assessment safety Ginkgo biloba L. leaf extract ( IDN 5933 ) human subject treat therapeutic dos term adverse drug reaction , hepatotoxicity , genotoxicity .</brief_summary>
	<brief_title>Safety Ginkgo Biloba Leaf Extract</brief_title>
	<detailed_description>The study randomise clinical trial compare subject receive twice-daily dos either 120-mg Ginkgo biloba L. leaf extract ( IDN 5933 ) placebo 6 month period . Primary Endpoints : - DNA Damage assess Comet assay proportion DNA tail . - Micronucleus frequency ( MN ) peripheral blood lymphocyte ( Frequency per 1000 binucleated cell ) . Secondary Endpoints : - Complete clinical assessment begin end study . - Occurrence Adverse drug reaction individual treat GBE placebo . - Liver function monitor accord biological laboratory examination clinical symptom . A subgroup individual monitor also genetic parameter concern expression pattern gene putatively associate early event HCC carcinogenesis Clinical biological parameter measure study group begin ( T0 ) end study ( T2 ) .</detailed_description>
	<mesh_term>Genomic Instability</mesh_term>
	<criteria>Male female senior , resident nurse home , know clinically significant pathology assess investigator Life expectancy great 1 year Subjects must give write informed consent accordance ICHGCP ( International Conference Harmonization Good Clinical Practice ) local law regulation To perform experiment typical population treat Ginkgo biloba L. leaf extract ( IDN 5933 ) study perform among resident nurse home among structure San Raffaele network , i.e. , The San Raffaele Montecompatri , San Raffaele Rocca di Papa San Raffaele Sabaudia . The use institutionalised subject allow good compliance treatment , administer nursing home nurse . Subjects meet inclusion criterion sign informed consent randomise receive 120mg/twice per day Ginkgo biloba L. leaf extract ( IDN 5933 ) placebo . Life expectancy less 1 year Treatment anticoagulant antiplatelet drug subject previous report increase bleeding tendency Cognitive impairment Refuse sign inform consent</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Ginkgo Biloba Extract</keyword>
	<keyword>Safety</keyword>
	<keyword>Genomic Stability</keyword>
	<keyword>DNA cell maintenance</keyword>
</DOC>